Did oral semaglutide reduce heart attacks in PIONEER-6?

No. Non-fatal MI was numerically higher with oral semaglutide (HR 1.18, 95% CI 0.73 to 1.90), though this difference was not statistically significant. The confidence interval includes both benefit and harm, so no conclusion can be drawn about MI specifically.

How large was the cardiovascular death reduction?

Cardiovascular death occurred in 15 patients on oral semaglutide versus 30 on placebo (HR 0.49, 95% CI 0.27 to 0.92). This 51% relative reduction is nominally significant, but the small number of events and the trial's non-inferiority design mean it should be considered a signal requiring confirmation, not a definitive finding.

Was PIONEER-6 long enough to detect cardiovascular benefit?

The median follow-up was 15.9 months, shorter than most GLP-1 CVOTs. This duration was sufficient to confirm non-inferiority for safety, but many researchers consider it too brief to reliably detect or exclude moderate-sized cardiovascular benefits. The SOUL trial was designed to address this gap with longer follow-up.

How does PIONEER-6 compare to SUSTAIN-6?

Both tested semaglutide in patients with type 2 diabetes and high cardiovascular risk. SUSTAIN-6 used injectable semaglutide (0.5 mg or 1.0 mg weekly) over a median of 2.1 years, finding a significant 26% MACE reduction (HR 0.74). PIONEER-6 used oral semaglutide 14 mg daily over a shorter period and showed a non-significant 21% reduction (HR 0.79). The molecule is the same; the formulation, dose exposure, and trial duration differ.

Why doesn't oral semaglutide have a cardiovascular benefit indication?

FDA cardiovascular benefit indications require a superiority finding from a trial designed and powered to test that hypothesis. PIONEER-6 was designed only for non-inferiority, and its upper confidence bound (1.11) crossed 1.0, so superiority was not demonstrated. The Rybelsus prescribing information does not carry a CV risk reduction claim.

Did subgroup analyses show different results for women versus men?

The point estimate for women (HR 0.72) was numerically lower than for men (HR 0.82), but the interaction p-value was 0.71, meaning this difference is easily attributable to chance. Women made up only 31.6% of the trial population, so the female subgroup had limited statistical power.

What side effects were most common with oral semaglutide in PIONEER-6?

Nausea affected 16% of the oral semaglutide group versus 6% of placebo. Discontinuation rates due to adverse events were 11.6% for semaglutide versus 6.5% for placebo. Gastrointestinal symptoms (nausea, diarrhea, decreased appetite) accounted for most of the difference.

How many MACE events occurred in total?

A total of 137 first MACE events were adjudicated: 61 in the oral semaglutide arm and 76 in the placebo arm. The trial required 122 events to reach its pre-specified statistical threshold for the non-inferiority analysis.

What was the non-inferiority margin and why does it matter?

PIONEER-6 used a margin of 1.8, meaning the upper bound of the MACE hazard ratio had to fall below 1.8 to confirm non-inferiority. This is wider than the 1.3 margin used in LEADER and SUSTAIN-6. A wider margin requires fewer events and allows a shorter trial, but it sets a lower bar for declaring safety. With the observed upper bound of 1.11, oral semaglutide cleared both the 1.8 and 1.3 thresholds.

PIONEER-6 Results in Detail: Numbers, Subgroups, and Time Course

Q: What was the primary endpoint of PIONEER-6?

The primary endpoint was time to first major adverse cardiovascular event (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. The trial tested whether oral semaglutide was non-inferior to placebo for this outcome.

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for PIONEER-6 Results in Detail: Numbers, Subgroups, and Time Course Image: HealthRX.com clinical image

PIONEER-6 Results in Detail: Numbers, Subgroups, and Time Course

At a glance

| Parameter | Detail | |---|---| | N | 3,183 (1:1 randomization) | | Intervention | Oral semaglutide 14 mg once daily | | Comparator | Placebo (both on standard of care) | | Duration | Median 15.9 months (event-driven) | | Primary endpoint | Time to first MACE (CV death, non-fatal MI, non-fatal stroke) | | Key result | HR 0.79 (95% CI 0.57 to 1.11); p <0.001 for non-inferiority | | Publication | Husain et al., NEJM 2019 |

Why This Trial Exists

The FDA requires cardiovascular outcomes trials (CVOTs) for all new glucose-lowering therapies, a mandate formalized in 2008 after the rosiglitazone controversy. By 2019, injectable semaglutide had already demonstrated cardiovascular benefit in the SUSTAIN-6 trial. PIONEER-6 posed the same question for the oral formulation: does oral semaglutide raise cardiovascular risk in patients with type 2 diabetes who already carry a heavy burden of atherosclerotic disease?

The trial was designed specifically to rule out excess cardiovascular harm, not to prove benefit. That distinction matters when interpreting every result that follows.

Population and Baseline Characteristics

PIONEER-6 enrolled adults aged 50 or older with established cardiovascular disease or chronic kidney disease, and adults aged 60 or older with cardiovascular risk factors alone. Roughly 85% of participants had established atherosclerotic disease at baseline. The population skewed older (mean age 66 years), predominantly male (68.4%), and had a mean diabetes duration of 14.9 years. Baseline HbA1c averaged 8.2%, and mean BMI was 32.3 kg/m².

About 85% were on metformin, 60% on insulin, and 76% on statins at enrollment. This is a medically complex, heavily treated cohort, which limits extrapolation to lower-risk patients but strengthens the cardiovascular safety signal in the population most likely to experience events.

Primary Endpoint: Three-Component MACE

The primary composite (first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) occurred in 61 of 1,591 patients (3.8%) on oral semaglutide versus 76 of 1,592 (4.8%) on placebo. The resulting hazard ratio was 0.79 (95% CI 0.57 to 1.11).

Non-inferiority was confirmed (p <0.001 against a pre-specified margin of 1.8). The trial was not powered for superiority testing, and indeed the upper bound of 1.11 crossed 1.0, so superiority was not established (p = 0.17).

| MACE Component | Oral Semaglutide n (%) | Placebo n (%) | HR (95% CI) | |---|---|---|---| | Composite MACE | 61 (3.8) | 76 (4.8) | 0.79 (0.57 to 1.11) | | CV death | 15 (0.9) | 30 (1.9) | 0.49 (0.27 to 0.92) | | Non-fatal MI | 37 (2.3) | 31 (1.9) | 1.18 (0.73 to 1.90) | | Non-fatal stroke | 12 (0.8) | 16 (1.0) | 0.74 (0.35 to 1.57) |

Two numbers stand out. Cardiovascular death was halved (HR 0.49, 95% CI 0.27 to 0.92), a statistically significant finding even in this underpowered context. Non-fatal MI ran numerically higher in the semaglutide arm (HR 1.18), though with wide confidence intervals that comfortably include no difference.

Secondary and Exploratory Endpoints

PIONEER-6 pre-specified several secondary endpoints. All-cause mortality showed a 49% reduction favoring oral semaglutide (HR 0.51, 95% CI 0.31 to 0.84). This result was nominally significant but falls outside the trial's hierarchical testing framework, so it should be interpreted as hypothesis-generating rather than confirmatory.

| Secondary Endpoint | Oral Semaglutide n (%) | Placebo n (%) | HR (95% CI) | |---|---|---|---| | All-cause death | 23 (1.4) | 45 (2.8) | 0.51 (0.31 to 0.84) | | Expanded MACE (+ UA, HF hosp) | 93 (5.8) | 108 (6.8) | 0.85 (0.64 to 1.12) | | MI (fatal + non-fatal) | 39 (2.5) | 33 (2.1) | 1.17 (0.74 to 1.86) | | Stroke (fatal + non-fatal) | 12 (0.8) | 16 (1.0) | 0.74 (0.35 to 1.57) | | Hospitalization for heart failure | 21 (1.3) | 24 (1.5) | 0.86 (0.48 to 1.55) |

The expanded MACE composite (adding unstable angina hospitalization and heart failure hospitalization) yielded an HR of 0.85 (95% CI 0.64 to 1.12). Heart failure hospitalization itself was numerically lower with semaglutide (HR 0.86), consistent with the modest weight loss observed in GLP-1 receptor agonist trials, though this too lacked statistical significance.

Time-Course Pattern

Kaplan-Meier curves for the primary MACE endpoint began to separate between 26 and 39 weeks after randomization. The separation widened progressively through week 78, at which point the majority of adjudicated events had accrued. Because PIONEER-6 was event-driven with a relatively short median follow-up of 15.9 months, the curves reflect a trial that achieved its required 122 primary events faster than anticipated, partly due to the high-risk population.

For cardiovascular death specifically, curve separation appeared earlier (by approximately week 20) and was more pronounced. This early divergence has been interpreted cautiously: short trial duration means that late-emerging risks or benefits may be missed, and the small absolute number of CV deaths (15 vs. 30) leaves the estimate susceptible to random variation.

The event rate in the placebo arm (4.8% over a median of 15.9 months) exceeded the protocol's assumptions, which accelerated trial completion but limited the total person-years of exposure. Longer trials such as SOUL were designed to address this gap.

Subgroup Analyses

Pre-specified subgroup analyses for the primary MACE composite showed consistent direction of effect across most strata. No subgroup demonstrated a statistically significant interaction with treatment.

| Subgroup | HR (95% CI) | Interaction p | |---|---|---| | Age <65 years | 0.68 (0.40 to 1.16) | 0.42 | | Age ≥65 years | 0.89 (0.58 to 1.36) |, | | Male | 0.82 (0.56 to 1.20) | 0.71 | | Female | 0.72 (0.38 to 1.38) |, | | Baseline HbA1c <8.0% | 0.65 (0.38 to 1.12) | 0.30 | | Baseline HbA1c ≥8.0% | 0.94 (0.60 to 1.47) |, | | Established CVD (yes) | 0.81 (0.57 to 1.14) | 0.73 | | Established CVD (no) | 0.66 (0.22 to 1.97) |, | | Baseline eGFR <60 | 0.85 (0.50 to 1.44) | 0.72 | | Baseline eGFR ≥60 | 0.74 (0.47 to 1.16) |, |

Patients younger than 65 and those with lower baseline HbA1c showed numerically greater point-estimate reductions, but wide confidence intervals in every subgroup prevent firm conclusions. The trial was not powered for subgroup comparisons.

Metabolic Outcomes in Context

HbA1c decreased by 1.0 percentage point more with oral semaglutide than with placebo at the end of the trial. Body weight decreased by 4.2 kg more in the semaglutide arm. These metabolic changes are consistent with the PIONEER program's phase 3 data, though PIONEER-6 was not designed to evaluate glycemic efficacy, and glycemic management by local investigators was permitted in both arms.

The relationship between these metabolic effects and the cardiovascular signal is uncertain. The all-cause mortality reduction (HR 0.51) is larger than what weight loss or glucose lowering alone would predict, suggesting possible direct vascular or anti-inflammatory mechanisms. The FDA label for oral semaglutide (Rybelsus) does not carry a cardiovascular benefit indication based on PIONEER-6 alone, reflecting the non-inferiority design.

Limitations the Authors Acknowledged

Several design features limit interpretation. The trial's short median duration (15.9 months) means effects that take years to manifest, such as atherosclerotic plaque stabilization, could not be captured. The event-driven design prioritized speed over depth.

The 1.8 non-inferiority margin is wider than the 1.3 margin used in some competitor CVOTs (for example, LEADER and SUSTAIN-6 both used 1.3). This choice was pragmatic, allowing a smaller sample size, but it means PIONEER-6 tolerates a higher ceiling of potential harm before failing.

Gastrointestinal side effects were more common with oral semaglutide (nausea in 16% vs. 6%; discontinuation for adverse events in 11.6% vs. 6.5%), which could have unblinded some patients and investigators. The study did not report whether unblinding influenced clinical decision-making.

The relatively low absolute event counts in individual MACE components (e.g., 15 CV deaths in the semaglutide arm) produce wide confidence intervals. The 51% reduction in CV death is striking but should be treated as a signal, not a settled estimate.

Placing PIONEER-6 in the GLP-1 CVOT Sequence

PIONEER-6 occupies a specific position in the GLP-1 cardiovascular evidence base. LEADER (liraglutide, 2016) was the first to show superiority for MACE in this drug class. SUSTAIN-6 (injectable semaglutide, 2016) showed a 26% MACE reduction. PIONEER-6 then confirmed oral semaglutide's cardiovascular safety, extending confidence in the molecule across formulations.

The pattern across these trials is consistent: semaglutide, whether injected or swallowed, does not increase cardiovascular risk, and the point estimates consistently favor active treatment. The SELECT trial (2023) later confirmed cardiovascular benefit for semaglutide 2.4 mg in patients with obesity and established CVD, though that trial used a higher injectable dose in a different population.

For clinicians, PIONEER-6 supports prescribing oral semaglutide to patients with type 2 diabetes and high cardiovascular risk without concern about excess MACE events. It does not, by itself, support prescribing oral semaglutide specifically for cardiovascular risk reduction. That distinction shapes formulary decisions and insurance coverage policies.

Frequently asked questions

›

References

Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851. PubMed
Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. PubMed
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. PubMed
U.S. Food and Drug Administration. Rybelsus (semaglutide) prescribing information. 2019. FDA Label
McGuire DK, Busui RP, Engel SS, et al. Oral semaglutide and cardiovascular outcomes in type 2 diabetes: the SOUL randomized clinical trial. JAMA. 2024. PubMed